Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Octreotide Acetate Microspheres in Healthy Volunteers
NCT06254235Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of Octreotide long-acting injection in acromegaly and neuroendocrine tumors (NETs) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area Under the Curve from Day 0 to Day 28, Area Under the Curve from Day 28 to Day 56 and 3 more. Started Jun 2021; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
acromegalyneuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT06254235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254235.